| Identification | Back Directory | [Name]
1-(5-(7-(3-morpholinopropoxy)quinazolin-4-ylthio)-1,3,4-thiadiazol-2-yl)-3-p-tolylurea | [CAS]
1370256-78-2 | [Synonyms]
AOB5016
SKLB477
CS-2113
SKLB4771
FLT3-IN-1
CHEMBL2046883
FLT3-IN-1, >98%
FLT3-IN-1(SKLB4771)
SKLB 4771;SKLB-4771
1-(5-(7-(3-morpholinopropoxy)quinazolin-4-ylthio)-1,3,4-thiadiazol-2-yl)-3-p-tolylurea
N-(4-Methylphenyl)-N'-[5-[[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]thio]-1,3,4-thiadiazol-2-yl]urea
Urea, N-(4-methylphenyl)-N'-[5-[[7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]thio]-1,3,4-thiadiazol-2-yl]- | [Molecular Formula]
C25H27N7O3S2 | [MDL Number]
MFCD28900746 | [MOL File]
1370256-78-2.mol | [Molecular Weight]
537.66 |
| Chemical Properties | Back Directory | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 47 mg/mL (87.42 mM) | [form ]
Solid | [pka]
6.62±0.50(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
FLT3-IN-1, is a FLT3 inhibitor. | [in vivo]
SKLB4771 (20-100 mg/kg; i.p.; once daily; 21 d) inhibits tumor growth in vivo without significant weight loss or any other obvious signs of toxicity on mice[1].
Pharmacokinetic Analysis of SKLB4771 in rat (40 mg/kg; i.p.)[1]
| Cmax (μg/mL) | T1/2 (h) | AUCmax (h·μg/mL) | Tmax (h) | CLobs (L/h/kg) | | 5.31 | 13.9 | 21.86 | 1.0 | 2.21 |
| Animal Model: | Female NOD-SCID mouse (6?7 weeks old)[1] | | Dosage: | 20, 40, 100 mg/kg; dissolved in 25% (v/v) PEG400 plus 5% DMSO, administered at a dose of 5 mL/kg | | Administration: | Intraperitoneal injection; once daily; 21 days | | Result: | Inhibited tumor growth by 66% and 84% at concentration of 20 mg/kg and 40 mg/kg, respectively.
Resulted cell proliferation inhibition and apoptosis induction. |
|
|
| Company Name: |
D&C Chemicals
|
| Telephone: |
+86-21-58447131 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList16963/0_EN.htm |
|